The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

This book discusses the benefits of application of different psychotherapy techniques, in addition to optimal medical approaches, in patients with ischemic heart disease. It explains the theoretical basis for use of these techniques, discusses the scientific evidence for their efficacy, and identifies important practical issues. Detailed attention is devoted to both well-established and recently developed approaches of proven value, as well as to future applications. In addition, practical insights are provided into the most effective ways of integrating psychotherapy with medical activities in hospitals, outpatient clinics, and rehabilitation centers. The authors are world experts in the fields of psychotherapy, pharmacology, and cardiology, who collectively provide a sound foundation for an interdisciplinary approach to patients with ischemic heart disease. Psychotherapy for Ischemic Heart Disease is both a textbook and a practical manual aimed particularly at cardiologists, psychologists, psychotherapists, and psychiatrists, but also internal medicine specialists, cardiac surgeons, general practitioners, rehabilitation doctors, students, nurses, and patients.

This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences.

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.

The second edition of Cognitive Therapy in Groups by Michael Free has been completely rewritten as a 25-session, structured programme of cognitive therapy in five modules. It is designed in an easy-to-present psycho-educational format that is intended for groups, but can also be used with individuals. It is sufficiently flexible for clinicians to use and adapt the resources for their own practice, and sufficiently specific to be used verbatim with a wide range of people suffering from emotional and behavioural problems. Web-based support resources include assessment tools, handouts and PowerPoint slides.

Recently, there has been a growing awareness of the multiple interrelationships between depression and various physical diseases. Patients with psychiatric problems, particularly depression, may be more susceptible to cardiovascular disorders. Depression and Heart Disease synthesizes current evidence, including some previously unpublished data, in a concise, easy-to-read format. The authors succinctly describe the epidemiology, pathogenesis (including cytokines and genetics), and risk factors of the comorbidity between depression and heart disease. The book also reviews the best pharmacological and psychotherapeutic approaches for people with this comorbidity.

The cardiovascular system transports oxygen and nutrients to all parts of the body; therefore, any impediment to this system through, for example, a circulatory disorder, represents a serious threat to organs, tissues, and cells. Obstructive diseases of vessels with a diameter of more than 1 mm can be treated by conventional surgical and interventional approaches; however, blockages in small vessels with a diameter of less than 1 mm cannot be treated by conventional methods. As a consequence, therapeutic ang- genesis and vasculogenesis for the treatment of ischemic diseases have been widely studied in the last decade. These methods may contribute to the re pair of intractable cardiovascular diseases with a main vascular involvement in the body's smallest vessels. In this book, Hikaru Matsuda and I have tried to summarize recent Japanese developments in the field of cardiovascular regeneration therapies using tissue engineering. The Ministry of Health, Labor, and Welfare of Japan has been encouraging the National Cardiovascular Center Research Institute to promote cardiovascular regeneration therapies using such ap proaches. Therefore, it is with the financial aid and support of research grants, such as that for Cardiovascular Disease (13C-1 and I6C-6), Health and Labor Sciences Research Grants (RHGTEFB-genome-005, RHGTEFB-saisei-003, and CRCD-junkanki-009) and a grant from NEDO of Japan, that significant progress has been possible.